Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | TEK | Q02763 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.51 |
| ▸ | RAF1 | P04049 | 10/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305473 | 1.00 | MAPK14 (0.58) | MAPK14TEKALOX5MAPK13MAPK12 | |
| SCHEMBL14060157 | 0.87 | MAPK13 (0.64) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL14060772 | 0.85 | MAPK13 (0.71) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL14060675 | 0.83 | MAPK13 (0.70) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL29642917 | 0.83 | PTPN1 (0.66) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL7159987 | 0.83 | PTPN1 (0.66) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL31305507 | 0.83 | MAPK14 (0.47) | MAPK14TEKALOX5MAPK11MAPK9 | |
| SCHEMBL14060041 | 0.83 | MAPK14 (0.47) | MAPK14TEKALOX5MAPK11MAPK9 | |
| SCHEMBL14060485 | 0.83 | MAPK13 (0.69) | MAPK14ALOX5MAPK13MAPK12MAPK11 | |
| SCHEMBL14060694 | 0.82 | MAPK13 (0.70) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4506488-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | Shikoku Chemicals Corporation (JP) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023190263-A1 | SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY | 四国化成工業株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-10398028-B2 | Surface treating composition for copper and copper alloy and utilization thereof | SHIKOKU CHEMICALS CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170064823-A1 | SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2017-03-02 | — | — | US | disclosed |
| US-9532493-B2 | Surface treating composition for copper and copper alloy and utilization thereof | SHIKOKU CHEMICALS CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| CN-103547706-B | Surface treatment composition for copper and copper alloy and use thereof | 四国化成工业株式会社 | 2016-09-28 | — | — | CN | disclosed |
| EP-2714962-B1 | SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF | SHIKOKU CHEM (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-20140097231-A1 | SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2014-04-10 | — | — | US | disclosed |
| CN-103547706-A | Surface treatment composition for copper and copper alloy and use thereof | SHIKOKU CHEM | 2014-01-29 | — | — | CN | disclosed |
| WO-2012161341-A1 | SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398028-B2 | Surface treating composition for copper and copper alloy and utilization thereof | SOD1, SOD3, AOC3 | MAPK14 882/4885TEK 4593/4885ALOX5 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.